Assay

Financial-condition grades for SEC filers

Company Report · as of Oct 9, 2026


HomeCompaniesSectorsCalendarLast night

Quince Therapeutics, Inc.QNCX · healthcare
GradeNonecomputable_factors_below_threshold: 6 of 14 inputs computable; 7 are required
Reliability0.83 AUCfailure model, filers with $12.5M to $120M assets; 95% interval 0.79 to 0.86; 201 events, 2020 to 2025
Peer failure rate1.07% a yearItem 1.03 bankruptcies, same asset band, 2012 to 2025
Size band$12.5M to $120M assetstotal assets $93.5M[1]
Warningsdilution, late filer, thin data, distress · fortress balance sheetnot computable: degenerate inputs
Inputs computable6 of 14
Graded fromfilings received through Apr 10, 2026182 days before the rescan; every figure keyed to the SEC receipt date
Last close$29.292026-10-08; market equity $29.8M; iex feed
Price used in gradeNone
Share price, twelve months to the rescansplit-adjusted close; a lollipop at every rescan carries the letter held then; baseline ticks are SEC receipt dates of the inputs; ranges and dragging scroll the full history
$500NovDecJanFebMarAprMayJunJulAugSepOct$29.36
ABCDE20132014201520162017201820192020202120222023202420252026

Percentile at every rescan on file, Jan 21, 2012 to Oct 9, 2026; stronger toward the top. Hover for the date.

Open this report as it stood on

Letter setLetterPercentileBand
Jan 21, 2012nonen/a
Mar 21, 2020nonen/aQ3
Mar 21, 2023nonen/aQ2
Apr 21, 2024nonen/aQ3
Apr 21, 2025nonen/aQ2

Each date opens the report as it stood on that rescan.

Business, in the company's words. Opening of Item 1 of the 10-K received Apr 10, 2026; the document on sec.gov.

We are a biotechnology company and, prior to the completion of our NEAT Phase 3 trial, described below, focused our development activities on unlocking the power of a patient’s own biology for the treatment of rare diseases. Our proprietary AIDE technology platform is an innovative drug/device combination that uses an automated process designed to encapsulate a drug into the patient’s own red blood cells. Red blood cells have several characteristics that make them an excellent vehicle for drug delivery, potentially including better safety and tolerability, enhanced tissue biodistribution, reduced immunogenicity, and prolongation of circulating half-life.

Warnings [top]

Dilution. split-adjusted year-over-year share growth is 270.5%[2-3]
Late filer. found 1 NT 10-K/Q filings in the last eight quarters
Thin data. 6 of 14 grade factors are computable; minimum is 7
Distress. CHS probability 4.759935%; universe top-decile threshold 1.068854%
Fortress balance sheet. cash minus debt is 5,809,000 USD; Altman Z is not used[4-5]

7 checks ran; none of them enters the letter. The checks are listed on the warnings screen.

The Fourteen Inputs [top]

Lower percentile is stronger. Source numbers open the SEC filing; a range that spans filings opens the sources table.

InputPercentile, 0 to 100ValueSourcePeer medianPercentilePeersPeriod end
Profitability, sleeve percentile 10.7
Gross profitabilitynot computable32.2%
one or more required annual facts are missing
Return on invested capitalnot computable9.3%
a prior annual debt, equity, and cash observation is required
Accruals ratio(40.9%)[1,6-8](6.6%)10.78112025-12-31
Gross margin stability, five yearsnot computable2.8 pts
five annual gross margins are required; found 0
Solvency, sleeve percentile 88.1
Twelve-month failure probability4.76%0.07%95.52482026-06-30
Altman Z double-prime(21.94)[1,9-14](0.31)74.87562025-12-31
Net debt to EBITDAnot computable1.82x
EBITDA must exceed $100,000
Interest coveragenot computable(4.51x)
one or more required annual facts are missing
Current ratio0.53x[9-10]2.96x93.98392025-12-31
Growth and financing, sleeve percentile 75.7
Revenue growth, three-year compoundnot computable10.0%
four annual observations are required; found 0
Free cash flow growth, three-year compoundnot computable10.9%
current FCF must be positive and base FCF must exceed $100,000
Reinvestment ratenot computable37.1%
pretax income must exceed the validity floor and imply a 0%-100% tax rate
Asset growth, three years(3.4%)[1,8,15-16]2.1%59.97042025-12-31
Net share issuance, one year270.5%[2-3]2.5%91.56342026-04-09

Gross profitability. Revenue less cost of goods sold, over total assets.

Accruals ratio. Net income less operating cash flow, over average assets; lower is stronger.

Gross margin stability, five years. Standard deviation of gross margin; lower is stronger.

Twelve-month failure probability. CHS model; lower is stronger.

Net debt to EBITDA. Lower is stronger.

Net share issuance, one year. Split-adjusted; lower is stronger.

Among 371 Peers [top]

What the Price Implies [top]

Market measures at the 2026-10-08 close. None enters the grade. Percentile among graded peers with the same measure.

MeasureValuePeer medianPercentileReading
Twelve-month price change, skipping the latest month(90.0%)8.0%2hotter than 2 of 100 peers
Distance from 52-week high(96.7%)(31.4%)2closer to its high than 2 of 100 peers
EBIT to enterprise valuenot computable(1.5%)enterprise value must exceed $100,000
Free cash flow yield(139.9%)(1.0%)4pricier than 96 of 100 peers
Book value to price(1.18)0.281pricier than 99 of 100 peers
Sales to pricenot computable0.31required accounting or market input is missing
Composite equity issuance, five years192.9%20.3%88more equity-funded than 88 of 100 peers
Relative strength against the sector, log excess return(2.52)(0.14)2ahead of 2 of 100 peers

Inputs: market equity $29.9M; EBIT -$58.1M; free cash flow -$41.8M; book equity -$35.3M; debt $0; cash $116.0M[17].

Diagnostics [top]

Diagnostics do not feed the grade.

Piotroski F-score: None of 9, period end 2025-12-31
Return on assets above zero(73.4%)✗ fail[6,8]
Operating cash flow above zero-$41.4M✗ fail[7]
Return on assets improved(39.5 pts)✗ fail[6,8,15,18]
Operating cash flow exceeds net income$42.6M✓ pass[6-7]
Long-term leverage fell(10.1 pts)✓ pass[1,5,8,15,19]
Current ratio improved(552.1 pts)✗ fail[9-10,20-21]
No new shares issued270.5%✗ fail[2-3]
Gross margin improvedn/a
Asset turnover improvedn/a[8,15]
Cash, filings, liquidity
Cash and equivalents$116.0M[22]
Operating cash flow, four quarters-$46.9M[7,22-26]
Months of runway29.7
Late filings, two years1
NT 10-K or NT 10-Q
Days since last periodic filing56
10-Q received Aug 14, 2026
Median daily dollar volume$746,364
63 sessions
Days since newest grade input182

Downloads [top]

Sources [top]

Every citation on this page. Filing opens the SEC index page for that submission; viewer opens the SEC interactive data for the same filing; series opens the SEC XBRL API record for that tag and company.

#ConceptXBRL tagValuePeriod endReceivedFormLinks
1assetsus-gaap:Assets$93.5M2025-12-312026-04-1010-Kfiling · viewer · series
2shares outstandingdei:EntityCommonStockSharesOutstanding163,007,9432026-04-092026-04-1010-Kfiling · viewer · series
3shares outstandingdei:EntityCommonStockSharesOutstanding44,001,6432025-03-132025-03-2410-Kfiling · viewer · series
4cashus-gaap:CashAndCashEquivalentsAtCarryingValue$5.8M2025-12-312026-04-1010-Kfiling · viewer · series
5total debtus-gaap:LongTermDebt$02025-12-312026-04-1010-Kfiling · viewer · series
6net incomeus-gaap:NetIncomeLoss-$84.0M2025-12-312026-04-1010-Kfiling · viewer · series
7operating cash flowus-gaap:NetCashProvidedByUsedInOperatingActivities-$41.4M2025-12-312026-04-1010-Kfiling · viewer · series
8assetsus-gaap:Assets$114.5M2024-12-312026-04-1010-Kfiling · viewer · series
9current assetsus-gaap:AssetsCurrent$22.9M2025-12-312026-04-1010-Kfiling · viewer · series
10current liabilitiesus-gaap:LiabilitiesCurrent$43.2M2025-12-312026-04-1010-Kfiling · viewer · series
11retained earningsus-gaap:RetainedEarningsAccumulatedDeficit-$460.5M2025-12-312026-04-1010-Kfiling · viewer · series
12operating incomeus-gaap:OperatingIncomeLoss-$58.1M2025-12-312026-04-1010-Kfiling · viewer · series
13book equityus-gaap:StockholdersEquity-$35.7M2025-12-312026-04-1010-Kfiling · viewer · series
14liabilitiesus-gaap:Liabilities$129.2M2025-12-312026-04-1010-Kfiling · viewer · series
15assetsus-gaap:Assets$167.9M2023-12-312025-03-2410-Kfiling · viewer · series
16assetsus-gaap:Assets$103.9M2022-12-312024-04-0110-Kfiling · viewer · series
17shares outstandingdei:EntityCommonStockSharesOutstanding1,017,0632026-08-072026-08-1410-Qfiling · viewer · series
18net incomeus-gaap:NetIncomeLoss-$56.8M2024-12-312026-04-1010-Kfiling · viewer · series
19long term debtus-gaap:LongTermDebt$14.3M2024-12-312026-04-1010-Kfiling · viewer · series
20current assetsus-gaap:AssetsCurrent$44.0M2024-12-312026-04-1010-Kfiling · viewer · series
21current liabilitiesus-gaap:LiabilitiesCurrent$7.3M2024-12-312026-04-1010-Kfiling · viewer · series
22cashus-gaap:CashAndCashEquivalentsAtCarryingValue$116.0M2026-06-302026-08-1410-Qfiling · viewer · series
23operating cash flowus-gaap:NetCashProvidedByUsedInOperatingActivities-$26.5M2026-06-302026-08-1410-Qfiling · viewer · series
24operating cash flowus-gaap:NetCashProvidedByUsedInOperatingActivities-$7.6M2026-03-312026-05-1110-Qfiling · viewer · series
25operating cash flowus-gaap:NetCashProvidedByUsedInOperatingActivities-$30.9M2025-09-302025-11-1210-Qfiling · viewer · series
26operating cash flowus-gaap:NetCashProvidedByUsedInOperatingActivities-$21.0M2025-06-302026-08-1410-Qfiling · viewer · series

Limitations [top]

Peer group. Sector assignment from four-digit SIC codes, hand-tuned and published. The grade under three alternative peer policies is tabled above.

Size. Within a sector the letter tracks size. Among graded filers in the smallest asset band, 72% grade E and 0% grade A; in the largest, 13% grade E and 21% grade A. Universe as of Oct 9, 2026.

Failure model. filings 2012-01-01 to 2019-12-31 fit, filings 2020-01-01 to 2025-12-31 test; status post hoc pending confirmation. pre-registered on 2026 filings once their 12-month outcome windows close; supported if the paired per-quintile gain over the pooled model has a lower bound above 0.05.

Input validity. Revenue or total assets at or below $100,000 sets the degenerate-inputs flag. An input whose denominator is at or below $100,000 is left not computable rather than ranked.

Returns. No input on this page has a post-2015 confidence interval on returns that excludes zero. The grade ranks reported financial condition and is not a return forecast.